Evolution of the Average Target: Nektar Therapeutics

Evolution of the Target Price: Nektar Therapeutics

Changes in Analyst Recommendations: Nektar Therapeutics

d6872db8e7e67d37dcfbcd6d3e2d28.HWcR3wXnmaf0P1iTt5AnV_JE_-TtXtpuGbjgp6zOg30.XjVT6GiG_9Kze3X9muhKEcIesLaLP-wdVeLZxOWb-zFnEV-SZLit4YZMKw~0cfc1d888f4c91b80b7a8da6c61d0bbe
09-23 Wedbush Cuts Price Target on Nektar Therapeutics to $50 From $80, Keeps Neutral Rating MT
07-22 Cantor Fitzgerald Initiates Nektar Therapeutics at Buy With $153 Price Target MT
05-11 Wedbush Cuts Price Target on Nektar Therapeutics to $80 From $95, Keeps Neutral Rating MT
04-20 Top Midday Gainers MT
04-20 Wedbush Lifts Price Target on Nektar Therapeutics to $95 From $70, Maintains Neutral Rating MT
03-24 Wedbush Initiates Nektar Therapeutics at Neutral With $70 Price Target MT
02-23 B. Riley Raises Price Target on Nektar Therapeutics to $150 From $105, Keeps Buy Rating MT
12-16 HC Wainwright Adjusts Nektar Therapeutics Price Target to $135 From $120, Maintains Buy Rating MT
11-08 Nektar Therapeutics Presents New Data from Rezpegaldesleukin Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation At Acaai 2025 Annual Scientific Meeting CI
25-10-22 Nektar Therapeutics Announces Data from Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation At ACAAI 2025 Annual Scientific Meeting CI
25-09-23 B. Riley Boosts Price Target on Nektar Therapeutics to $105 From $85, Keeps Buy Rating MT
25-09-18 Sector Update: Health Care Stocks Advance Late Afternoon MT
25-06-24 BTIG Raises Nektar Therapeutics' Price Target to $100 From $60, Buy Rating Maintained MT
25-04-11 Nektar Therapeutics Shares Rise After Upgrade From Jefferies MT
25-04-11 Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1 MT
25-03-14 Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer MT
25-03-14 Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target is $6 MT
25-01-08 B. Riley Starts Nektar Therapeutics With Buy Rating, $4 Price Target MT
24-12-10 HC Wainwright Initiates Nektar Therapeutics at Buy With $6.50 Price Target MT
24-03-05 Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating MT
23-11-09 TD Cowen Upgrades Nektar Therapeutics to Outperform From Market Perform MT
23-05-10 Jefferies Upgrades Nektar Therapeutics to Hold From Underperform, Adjusts Price Target to $1 From $1.50 MT
23-03-06 Oppenheimer Adjusts Nektar Therapeutics Price Target to $3 From $5, Maintains Perform Rating MT
23-02-27 Goldman Sachs Adjusts Price Target on Nektar Therapeutics to $2 From $3, Maintains Sell Rating MT
23-02-24 Jefferies Downgrades Nektar Therapeutics to Underperform From Hold, Adjusts Price Target to $1.50 From $3.20 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+147.81%
+15.19%
+22.02%
+9.85%
+68.92%
+18.94%
+7.76%
+20.98%
-7.69%
+32.69%
Average +33.65%
Weighted average by Cap. +21.87%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
60.40USD
Average target price
141.40USD
Spread / Average Target
+134.11%
High Price Target
192.00USD
Spread / Highest target
+217.88%
Low Price Target
50.00USD
Spread / Lowest Target
-17.22%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. NKTR Stock
  4. Consensus Nektar Therapeutics